Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Operations (2023 - 2025)

Compass Therapeutics' Cash from Operations history spans 3 years, with the latest figure at 13254000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 44.66% year-over-year to 13254000.0; the TTM value through Dec 2025 reached 49143000.0, down 9.56%, while the annual FY2025 figure was 49143000.0, 9.56% down from the prior year.
  • Cash from Operations for Q4 2025 was 13254000.0 at Compass Therapeutics, down from 10849000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5922000.0 in Q3 2023 and bottomed at 13888000.0 in Q1 2024.
  • The 3-year median for Cash from Operations is 11441500.0 (2024), against an average of 11218000.0.
  • The largest YoY upside for Cash from Operations was 25.84% in 2024 against a maximum downside of 86.61% in 2024.
  • A 3-year view of Cash from Operations shows it stood at 12354000.0 in 2023, then rose by 25.84% to 9162000.0 in 2024, then tumbled by 44.66% to 13254000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Cash from Operations are 13254000.0 (Q4 2025), 10849000.0 (Q3 2025), and 11832000.0 (Q2 2025).